Contact PR

To use this feature, join Babbler easily !

arrow_back

Babbler allows PR people and reporters to collaborate a better way.

By joining Babbler you will be able to access hundreds of newsrooms and PR contacts from your industrie(s) and also share with them your upcoming needs.

Their newsrooms are already on Babbler

You're 1 click away from signing up

Previous

Nice to see you again !

Press release

EMA to review sotagliflozin as potential treatment for type 1 diabetes treatment
timer minutes reading time minute reading time

Copy link

Click to get original image size

The European Medicines Agency (EMA) has accepted for review Sanofi’s regulatory submission for sotagliflozin. If approved, the oral treatment would be used as an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus. Developed in partnership with Lexicon Pharmaceuticals, Inc., sotagliflozin is an investigational dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys process blood sugar (glucose).

Despite recent advances, the challenges of type 1 diabetes management prevent many patients from reaching their treatment goals. There is a need for therapies to be used in addition to insulin to help people with type 1 diabetes better control their blood sugar. Sotagliflozin is the first SGLT-1/2 dual inhibitor to be accepted for regulatory review in Europe,” says Jorge Insuasty, Senior-Vice President, Global Head of Development, Sanofi. “We look forward to working with the EMA through the review process to bring this potential treatment to patients.



  • Health & Medicine
  • Medicine
inscrit avec succès

Congratulations, you're registered on Babbler!

Discover now all the news waiting for you on Babbler: visit your newsfeed.!

Your topics have been selected, you can change it by clicking here

  • Health & Medicine
  • Medicine